Publication protocol
The human breast cancer cell lines MDA-MB-231, MDA-MB-468, MCF-7, and T47D were obtained from ATCC (Manassas, VA, USA). MDA-MB-231, MCF-7, and T47D cells were cultured in DMEM/Ham´s F12 (Gibco Life Technologies, Darmstadt, Germany) and MDA-MB-468 cells in DMEM (Gibco Life Technologies, Darmstadt, Germany), supplemented with 10% fetal bovine serum (FBS; Biochrome, Berlin, Germany) and 1% penicillin/streptomycin (Gibco Life Technologies). Cells were grown in a humidified atmosphere of 95% air and 5% CO2. Short tandem repeat profiling of all used cell lines was performed in August 2017 at the DSMZ (German Collection of Microorganisms and Cell Cultures) to verify their genetic authenticity. MDA-MB-468 cells were newly acquired.
To establish a simvastatin-resistant MDA-MB-231 subclone, cells were persistently treated over a time period of 4–5 months with simvastatin starting with 2–5 µM and a stepwise increase in concentration up to 25 µM (Suppl. Fig. 1a). In the first weeks, treatment was performed as an “on/off” regimen, stopped when cells microscopically underwent apoptosis and restarted when remaining vital cells had recovered. Later, regimen was changed to a regular treatment of every 2–3 days and finally to a daily treatment with splitting of the cells on Fridays with no treatment over the weekend. Control cells were treated with respective DMSO concentrations using the same regimen. Experiments were started when the cells no longer showed any microscopic sign of apoptosis.
Full paper
Login or
join for free to view the full paper.
Videos
Check out videos that might be relevant for performing Mammalian cell culture media T47D using DMEM/F-12 from Thermo Fisher Scientific. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.
We haven't found any additional videos for this experiment / product combination yet.